QTTB
NASD Q32 Bio Inc$10.42 ↑ +0.89 (+9.34%) Trading Up from the previous close of $9.53
- YTD change
- +213.86%
- vs 20-day SMA
- -4.93%
- vs 200-day SMA
- +20.51%
Price ranges
Price & Performance
+3.63 (+61.53%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 80.6% away from all-time highs of $53.79
- QTTB is up 214% since the beginning of the year
- QTTB is up 426% over the past 12 months
- QTTB is down 30% over the past 1 month
- 13% of all QTTB investors are betting against QTTB
QTTB reads neutral: price sits above one of the two key moving averages, the 12-month move is +381.3%.
- Previous minute
- -$0.18
- Last hour
- +$0.00
- Last 5 days
- -1.42%
- vs 8-day SMA
- +7.02%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David S. Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
